Milestone Pharmaceuticals Inc. Investment Income, Nonoperating
Milestone Pharmaceuticals Inc. (MIST) reported Investment Income, Nonoperating of $40.00 thousand for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-12.
Discontinued › Income Statement › Other Income
us-gaap:InvestmentIncomeNonoperating · last filed 2022-05-12
- Milestone Pharmaceuticals Inc. investment income, nonoperating for the quarter ending 2022-03-31 was $40.00K, a 50.00% decline year-over-year.
- Milestone Pharmaceuticals Inc. investment income, nonoperating for the quarter ending 2021-12-31 was $34.00K, a 64.58% decline year-over-year.
- Milestone Pharmaceuticals Inc. investment income, nonoperating for the quarter ending 2021-09-30 was $48.00K, a 46.07% decline year-over-year.
- Milestone Pharmaceuticals Inc. investment income, nonoperating for the quarter ending 2021-06-30 was $58.00K, a 53.97% decline year-over-year.
- Milestone Pharmaceuticals Inc. investment income, nonoperating for fiscal 2021 was $220.00K, a 69.70% decline from fiscal 2020.
- Milestone Pharmaceuticals Inc. investment income, nonoperating for fiscal 2020 was $726.00K, a 72.03% decline from fiscal 2019.
- Milestone Pharmaceuticals Inc. investment income, nonoperating for fiscal 2019 was $2.60M, a 265.12% increase from fiscal 2018.
- Milestone Pharmaceuticals Inc. investment income, nonoperating for fiscal 2018 was $711.00K.
| Period end | Investment Income, Nonoperating 3 month | Investment Income, Nonoperating 6 month | Investment Income, Nonoperating 9 month | Investment Income, Nonoperating 12 month |
|---|---|---|---|---|
| 2022-03-31 | $40.00K 10-Q · filed 2022-05-12 | $74.00K derived: sum of 2 quarters · filed 2022-05-12 | $122.00K derived: sum of 3 quarters · filed 2022-05-12 | $180.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2021-12-31 | $34.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $82.00K derived: sum of 2 quarters · filed 2022-03-24 | $140.00K derived: sum of 3 quarters · filed 2022-03-24 | $220.00K 10-K · filed 2022-03-24 |
| 2021-09-30 | $48.00K 10-Q · filed 2021-11-12 | $106.00K derived: sum of 2 quarters · filed 2021-11-12 | $186.00K 10-Q · filed 2021-11-12 | $282.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2021-06-30 | $58.00K 10-Q · filed 2021-08-11 | $138.00K 10-Q · filed 2021-08-11 | $234.00K derived: sum of 3 quarters · filed 2022-05-12 | $323.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2021-03-31 | $80.00K 10-Q · filed 2022-05-12 | $176.00K derived: sum of 2 quarters · filed 2022-05-12 | $265.00K derived: sum of 3 quarters · filed 2022-05-12 | $391.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $96.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $185.00K derived: sum of 2 quarters · filed 2022-03-24 | $311.00K derived: sum of 3 quarters · filed 2022-03-24 | $726.00K 10-K · filed 2022-03-24 |
| 2020-09-30 | $89.00K 10-Q · filed 2021-11-12 | $215.00K derived: sum of 2 quarters · filed 2021-11-12 | $630.00K 10-Q · filed 2021-11-12 | $1.23M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $126.00K 10-Q · filed 2021-08-11 | $540.00K 10-Q · filed 2021-08-11 | $1.14M derived: sum of 3 quarters · filed 2021-08-11 | $1.97M derived: sum of 4 quarters · filed 2021-08-11 |
| 2020-03-31 | $415.00K 10-Q · filed 2021-05-17 | $1.02M derived: sum of 2 quarters · filed 2021-05-17 | $1.84M derived: sum of 3 quarters · filed 2021-05-17 | $2.51M derived: sum of 4 quarters · filed 2021-05-17 |
| 2019-12-31 | $603.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $1.42M derived: sum of 2 quarters · filed 2021-03-29 | $2.10M derived: sum of 3 quarters · filed 2021-03-29 | $2.60M 10-K · filed 2021-03-29 |
| 2019-09-30 | $821.00K 10-Q · filed 2020-11-13 | $1.49M derived: sum of 2 quarters · filed 2020-11-13 | $1.99M 10-Q · filed 2020-11-13 | $2.44M derived: sum of 4 quarters · filed 2020-11-13 |
| 2019-06-30 | $672.00K 10-Q · filed 2020-08-12 | $1.17M 10-Q · filed 2020-08-12 | $1.62M derived: sum of 3 quarters · filed 2020-10-23 | $1.70M derived: sum of 4 quarters · filed 2020-10-23 |
| 2019-03-31 | $500.00K 10-Q · filed 2020-05-14 | $946.00K derived: sum of 2 quarters · filed 2020-10-23 | $1.03M derived: sum of 3 quarters · filed 2020-10-23 | $1.12M derived: sum of 4 quarters · filed 2020-10-23 |
| 2018-12-31 | $446.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2020-10-23 | $531.00K derived: sum of 2 quarters · filed 2020-10-23 | $620.00K derived: sum of 3 quarters · filed 2020-10-23 | $711.00K 10-K/A · filed 2020-10-23 |
| 2018-09-30 | $85.00K 10-Q · filed 2019-11-13 | $174.00K derived: sum of 2 quarters · filed 2019-11-13 | $265.00K 10-Q · filed 2019-11-13 | |
| 2018-06-30 | $89.00K 10-Q · filed 2019-08-13 | $180.00K 10-Q · filed 2019-08-13 | ||
| 2018-03-31 | $90.00K 10-Q · filed 2019-06-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B |